Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Montaser

Showing results (581-590 of 613) with videos related to

Pageof 62
Sort By:
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
BMC Pediatrics|June 10, 2026
Genotypic and phenotypic features of 23 Egyptian patients with tuberous sclerosis complexAmr A Othman, Abdelrahim A Sadek, Mohammed A Aladawy, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced MelanomaAntoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
JTO Clinical and Research Reports|December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung CancerMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
European Journal of Immunology|December 18, 2025
Diurnally-Regulated Corticosterone and Melatonin Inversely Control Endotoxin-Induced Acute Immune ResponsesMontaser Haddad, Sebastien Trzebanski, Ramon Bossardi Ramos, et al.
Nature Biotechnology|March 4, 2022
Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cellsDiego Balboa, Tom Barsby, Väinö Lithovius, et al.
Pageof 62

Showing results (581-590 of 613) with videos related to

Sort By:
Pageof 62
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
BMC Pediatrics|June 10, 2026
Genotypic and phenotypic features of 23 Egyptian patients with tuberous sclerosis complexAmr A Othman, Abdelrahim A Sadek, Mohammed A Aladawy, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced MelanomaAntoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
JTO Clinical and Research Reports|December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung CancerMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
European Journal of Immunology|December 18, 2025
Diurnally-Regulated Corticosterone and Melatonin Inversely Control Endotoxin-Induced Acute Immune ResponsesMontaser Haddad, Sebastien Trzebanski, Ramon Bossardi Ramos, et al.
Nature Biotechnology|March 4, 2022
Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cellsDiego Balboa, Tom Barsby, Väinö Lithovius, et al.
Pageof 62